Cargando…
Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) have emerged as a very promising therapeutic option for the treatment of many difficult-to-treat cancers and a number of clinical trials have explored their efficacy in malignant pleural mesothelioma patients. ICIs were initially evaluated in the s...
Autores principales: | Terenziani, Rita, Zoppi, Silvia, Fumarola, Claudia, Alfieri, Roberta, Bonelli, Mara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200040/ https://www.ncbi.nlm.nih.gov/pubmed/34199722 http://dx.doi.org/10.3390/cancers13112793 |
Ejemplares similares
-
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
por: Terenziani, Rita, et al.
Publicado: (2022) -
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
por: Bonelli, Mara, et al.
Publicado: (2020) -
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022) -
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells
por: Coccè, Valentina, et al.
Publicado: (2021) -
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells()
por: Bonelli, Mara A., et al.
Publicado: (2017)